Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials, and Trends, 2024

Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials, and Trends, 2024

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs enable the T-cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.

Between 2017 and today, nine CAR-T products reached commercialization, and this number is estimated to reach double-digits soon. Of these, six are U.S.FDA-approved CAR-T cell therapies, each of which have received approvals in other major healthcare markets as well. The six U.S. FDA approved products include:

Kymriah (tisagenlecleucel)
Yescarta (axicabtagene ciloleucel)
Tecartus (brexucabtagene autoleucel)
Breyanzi (lisocabtagene maraleucel)
Abecma (idecabtagene vicleucel)
Carvykti (ciltacabtagene autoleucel)
In addition, two CAR-T therapies have received approval from the Chinese National Medical Products
Administration (NMPA), Relma-cel and Yuanruida, and one CAR-T cell therapy has received approval from
the Indian Central Drugs Standard Control Organisation (CDSCO), NexCAR19.

These historic approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. M&A activity has been particularly aggressive, with Celgene snagging Juno Therapeutics for $9 billion and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.

For the progress of CAR-T cell therapies, the industry will need to continue to innovate and mitigate key challenges. Several CAR-T players have started to use efficient gene-transfer tools to impregnate T-cells with CARs and numerous partnerships are underway to develop CRISPR and electroporation technologies to modify T-cells. Some companies also use “on-off” switches that can turn off CAR-T cells to prevent toxicity. Unfortunately, the goal of achieving success with solid tumors remains elusive with clinical trials producing a low response rate. Thus, ongoing efforts within the CAR-T sector are focused on discovering effective solid tumor-specific antigens.

Currently, all of the nine marketed CAR-T cell therapy products and nearly three-quarters (75%) of the ongoing clinical trials utilize an autologous treatment approach. The next frontier for CAR-T cell therapies will be the development of allogeneic CAR-T cell therapies and their eventual approvals.

This billion dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are now proliferating in all major healthcare markets worldwide.

Key questions answered in this report include:

What are anticipated developments within the CAR-T sector? What commercial opportunities and patient outcomes will they unlock?
How many automated manufacturing systems are available within the global market?
What are the most targeted antigens for liquid and solid cancers?
How many CAR-T-related patent publications and granted patents were issued from 2012 to present?
Which countries have the largest number of CAR-T patents?
Which companies have filed the largest number of CAR-T patents?
Who are the top CAR-T patent inventors worldwide?
How many clinical trials were registered between 2003 and present?
Which biomarker antigens dominate in the CAR-T clinical trial landscape?
Which are the most common indications addressed by clinical trials in the U.S. and China?
Who are the U.S., Chinese, and European companies involved in CAR-T-related clinical trials?
How many deals have been signed within the CAR-T sector within the past year?
What are promising CAR-T candidates that could soon reach commercialization?
How are CAR-T therapies reimbursed within the U.S. and Europe?
What are the barriers, risks, and opportunities for growth within the global CAR-T industry?
Who are the major companies that are developing CAR-T cell therapies? What products and technologies do they have under development?
And many more…